ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -5 مورد

SARS-CoV-2 variants: Omicron sublineages[1-3]

SARS-CoV-2 variants: Omicron sublineages[1-3]
Notable Omicron sublineages Comments Circulating widely in 2025?
BA.1.1.529
  • Original Omicron variant
  • Designated a Variant of Concern in November 2021
 No
BA.4/BA.5
  • Bivalent COVID-19 vaccines in the United States were based on BA.4/BA.5 and original virus spike proteins
 No
XBB/XBB.1/XBB.1.5/XBB.1.6
  • Recombinant of BA.2.10.1 and BA.2.75 sublineage
  • 2023 to 2024 formula COVID-19 vaccines were based on the XBB.1.5 spike protein
 No
JN.1
  • Descendant of BA.2.86 sublineage, which had multiple spike protein mutations compared with its parent lineage, BA.2
  • Has mutation F456L*
  • Updated 2024 to 2025 formula adjuvanted recombinant COVID-19 vaccine is based on spike protein of JN.1
  • Recognized by the monoclonal antibody pemivibart[4]
 No
KP.2/KP.3/KP.3.1.1
  • Descendants of JN.1
  • Have mutation F456L*
  • Updated 2024 to 2025 formula mRNA COVID-19 vaccines are based on spike protein of KP.2
  • Recognized by the monoclonal antibody pemivibart (although less strongly than for JN.1)[4]
 Yes (KP.3.1.1)
XEC
  • Descendant of JN.1 (KS.1.1 and KP.3.3 lineages)
  • Has mutation F456L*
  • Limited immune escape from KP.2- or JN.1-based mRNA vaccines
  • Recognized by the monoclonal antibody pemivibart (although less strongly than for JN.1)[1]
 Yes
LP8.1
  • Descendant of JN.1 (KP.1.1.3 lineage)
  • Has mutations F456L and R346T*
  • Comparable immune escape as XEC
 Yes

SARS-CoV-2 variants are designated "Variants of Concern" if they are more transmissible, associated with greater risk of severe disease, substantially evade neutralization by vaccine- or infection-induced antibodies, result in reduced antiviral effectiveness, or escape detection by diagnostic tests. The Omicron parent variant (B.1.1.529) was designated a Variant of Concern in late 2021. Since then, Omicron sublineages have been the predominant circulating variants globally. Prior Variants of Concern that are no longer circulating are the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants.

In the United States, the proportion of circulating variants in each state can be found on the CDC website.

CDC: United States Centers for Disease Control and Prevention.

* Mutation F456L is located in the spike receptor binding domain and predicts escape from antibody neutralization.

References:
  1. Tracking SARS-CoV-2 variants. World Health Organization. https://www.who.int/activities/tracking-SARS-CoV-2-variants (Accessed on February 3, 2025).
  2. COVID Data Tracker – Summary of variant surveillance. Centers for Disease Control and Prevention. https://covid.cdc.gov/covid-data-tracker/#variants-genomic-surveillance (Accessed on February 3, 2025).
  3. COVID-19 Real-Time Learning Network: COVID-19 variant update. Centers for Disease Control and Prevention and the Infectious Diseases Society of America. https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#/+/0/publishedDate_na_dt/desc/ (Accessed on September 17, 2024).
  4. Fact sheet for healthcare providers: Emergency use authorization of Pemgarda (pemivibart). Invivyd, Inc. https://www.fda.gov/media/177067/download (Accessed on February 3, 2025).
Graphic 131216 Version 27.0